1. A method of merging Basic Service Set (BSS) and mesh traffic comprising:
sharing a same channel for mesh traffic and BSS traffic, the sharing a channel comprising at least one of a group consisting of:
reserving a channel for BSS traffic by a Mesh Access Point (MAP), said reserving comprising sending one of a group consisting of a CC-RTS and a CC-CTS addressed to said MAP; and
blocking use of the channel by a BSS station when the channel is not reserved, said blocking use of the channel comprising said MAP sending a frame setting a NAV in the BSS, wherein said blocking use of the channel by a BSS station comprises said MAP sending a frame on the BSS channel that sets the NAV of the stations in the BSS, wherein said MAP sending a frame comprises said MAP sending a QoS CF-Poll frame addressed to said MAP, and wherein MPs hearing said QoS poll, said QoS poll having a same first address and second address field in a MAC header of said frame and wherein said frame has a non-zero duration field, disregard said frame.
2. The method of claim 1 wherein said sending one of a group consisting of a CC-RTS and a CC-CTS comprises sending one of a group consisting of a CC-RTS and a CC-CTS indicating the data channel the MAP has selected for use in the BSS and a length of time interval said BSS will have use of said channel.
3. The method of claim 2 further comprising at least one of a group consisting of stations in said BSS transmitting to said MAP during said time interval, stations in said BSS transmitting to other stations in said BSS during said time interval, and said MAP transmitting to said stations in said BSS during said time interval.
4. The method of claim 2 further comprising said MAP refraining from reserving said channel again until a predetermined time period has elapsed.
5. The method of claim 1 wherein said QoS CF-Poll frame includes a time interval that the BSS stations refrain from accessing the channel.
6. A method of merging Basic Service Set (BSS) and mesh traffic comprising:
sharing a same radio for mesh traffic and BSS traffic, said radio switchable between serving said BSS and serving said mesh, wherein said sharing a radio comprises:
blocking use of the channel by a BSS station when the channel is not reserved, said blocking use of the channel comprising said MAP sending a frame setting a NAV in the BSS; and
setting the radio to a data channel and transmitting mesh traffic during a time interval of said NAV, wherein said MAP sending a frame comprises said MAP sending a QoS CF-Poll frame addressed to said MAP, wherein MPs hearing said QoS poll, said QoS poll having a same first address and second address field in a MAC header of said frame and wherein said frame has a non-zero duration field, disregard said frame.
7. A communication system comprising at least one BSS and at least one MAP, at least one of said BSS and said MAP comprising:
a memory;
a processor;
a communications interface;
an interconnection mechanism coupling the memory, the processor and the communications interface; and
wherein the memory is encoded with a BSS and mesh traffic merging application that when performed on the processor, provides a process for processing information, the communication system capable of performing the operations of:
sharing a same channel for mesh traffic and BSS traffic, the sharing a channel comprising at least one of a group consisting of:
reserving a channel for BSS traffic by a Mesh Access Point (MAP), said reserving comprising sending one of a group consisting of a CC-RTS and a CC-CTS addressed to said MAP; and
blocking use of the channel by a BSS station when the channel is not reserved, said blocking use of the channel comprising said MAP sending a frame setting a NAV in the BSS, wherein said blocking use of the channel by a BSS station comprises said MAP sending a frame that sets the NAV in the BSS, wherein said MAP sending a frame comprises said MAP sending a QoS CF-Poll frame addressed to said MAP, wherein said QoS CF-Poll frame includes a time interval that the BSS stations refrain from accessing the channel, and wherein said communication system is further capable of MPs hearing said QoS poll, said QoS poll having a same first address and second address field in a MAC header of said frame and wherein said frame has a non-zero duration field, disregard said frame.
8. The communication system of claim 7 wherein said operation of sending one of a group consisting of a CC-RTS and a CC-CTS comprises sending one of a group consisting of a CC-RTS and a CC-CTS indicating the data channel the MAP has selected for use in the BSS and a length of time interval said BSS will have use of said channel.
9. The communication system of claim 8 wherein said communication system is further capable of at least one of a group consisting of stations in said BSS transmitting to said MAP during said time interval, said BSS transmitting to other stations in said BSS during said time interval, and said MAP transmitting to said stations in said BSS during said time interval.
10. The communication system of claim 7 wherein said communication system is further capable of said MAP refraining from reserving said channel again until a predetermined time period has elapsed.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A novel compound represented by the following general formula (I), and the pharmaceutically acceptable salt thereof:
wherein
R1 is at least one selected from the group consisting of a hydrogen atom, C1-C6 alkyl group, C2-C6 alkyl ketone group and \u2014(CH2)n-Q, of which Q is an ether group or amine group substituted with C1-C6 lower alkyl group;
R2 is a hydrogen atom, or an ether group or thio group substituted with C1-C6 alkyl group;
R3 is a group selected from following substituents of general formula (Ia), (Ib), (Ic) or (Id),
wherein R\u2032 is a hydrogen atom, or C1-C6 alkyl group,
X is at least one selected from amine group unsubstituted or substituted with O, S or R\u2033, of which R\u2033 is a benzyl group substituted with ester group or carboxyl group,
n is an integer of 0-9;
wherein R\u2032\u2033 is at least one selected from a hydrogen atom, C1-C6 alkyl group or benzyl group,
n is an integer of 0-9;
wherein P1, P2 is independently, at least one selected from the group consisting of a hydrogen atom, C1-C6 alkyl group, phenyl group, benzyl group and 2-methyl-3-acetamide group,
n is an integer of 0-9;
wherein X is C, O, S or N atom,
m is an integer of 0 or 1,
Q is a phenyl group substituted with C1-C3 alkyl group, halogen atom, or nitro group,
n is an integer of 0-9.
2. The compound according to claim 1, wherein R1 is a methyl group, ethyl group, methylketone group or ethyl ketone group; Q is a methoxy group, an ethoxy group, dimethylamino group or diethylamino group; R2 is a hydrogen atom or methylthio group; R3 is selected from the group of general formula (Ia) wherein X is an oxygen atom or an ester group substituted with benzyl group; a group of general formula (Ib) wherein R\u2032\u2033 is a methyl group, an ethyl group or a benzyl group; a group of general formula (Ic) wherein P1, P2 is independently a methyl group, an ethyl group, a dimethyl group, diethyl group or 2-methyl-3-acetamide group; a group of general formula (Id) wherein Q is a phenyl group substituted with a methyl group or an ethyl group are
3. The compound according to claim 1, wherein said compound is selected from the group consisting of:
3-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-yl-1-propanol,
2-methoxy-4-5-(3-methoxy-propyl)-3-methylsulfanyl-benzofuran-2-yl-1-phenol,
2-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-yl-1-ethanol,
2-methoxy-4-5-(2-methoxy-ethyl)-3-methylsulfanyl-benzofuran-2-yl-phenol,
3-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-benzofuran-5-yl-1-propanol,
2-methoxy-4-5-(3-methoxy-propyl)-benzofuran-2-yl-phenol,
2-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-benzofuran-5-yl-1-ethanol,
3-2-(3,4-dimethoxyphenyl)-3-methylsufanyl-benzofuran-5-yl-propan-1-ol,
2-(3,4-dimethoxyphenyl)-5-(3-methoxy-propyl)-3-methylsufanyl-benzofuran,
2-2-(3,4-dimethoxyphenyl)-3-methylsufanyl-benzofuran-5-yl-ethanol,
2-(3,4-dimethoxyphenyl)-5-(2-methoxy-ethyl)-3-methylsufanyl-benzofuran,
3-2-(3,4-dimethoxy-phenyl)-benzofuran-5-yl-propan-1-ol,
2-(3,4-dimethoxy-phenyl)-5-(3-methoxy-propyl)-benzofuran,
2-2-(3,4-dimethoxy-phenyl)-benzofuran-5-yl-ethanol,
2-(3,4-dimethoxy-phenyl)-5-(2-methoxy-ethyl)-benzofuran,
3-2-{4\u2032-3-(diethylamino)propoxy-3\u2032-methoxy-phenyl}-3-(methylthio)-benzofuran-5-yl-1-propanol,
2-(3-methoxy-4-methoxymethoxy-phenyl)-5-(3-methoxy-propyl)-3-methylsulfanyl-benzofuran,
5-(2-methoxy-ethyl)-2-(3-methoxy-4-methoxymethoxy-phenyl)-3-methylsulfanyl-benzofuran,
3-2-{4\u2032-3-(diethylamino)propoxy-3\u2032-methoxy-phenyl}-3-benzofuran-5-yl-1-propanol,
3-2-{4\u2032-hydroxy-3\u2032-methoxy-phenyl}-3-(methylthio)-benzofuran-5-yl-propylamine,
Benzyl N-3-2-{4\u2032-hydroxy-3\u2032-methoxyphenyl}-3-(methylthio)-benzofuran-5-yl-propylcarbamate,
2-2-{4\u2032-hydroxy-3\u2032-methoxy-phenyl}-3-(methylthio)-benzofuran-5-yl-ethylamine,
Benzyl N-2-2-{4\u2032-hydroxy-3\u2032-methoxyphenyl}-3-(methylthio)-benzofuran-5-yl-ethylcarbamate,
2-(2-(3,4-Dimethoxyphenyl)-3-(methylthio)benzofuran-5-yl)propanoic acid
5-Allyloxy-2-(3,4-dimethoxy-phenyl)-benzofuran,
2-(3,4-dimethoxyphenyl)-N-propylbenzofuran-5-amine,
2-(3,4-Dimethoxy-phenyl)-5-propoxy-benzofuran;
Methyl 3-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-yl-propionate,
Benzyl 2-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-yl-propionate,
3-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-yl-propionic acid,
Methyl 2-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-yl-acetate,
Benzyl 2-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-yl-acetate,
2-2-(4\u2032hydroxy-3\u2032methoxyphenyl)-3-(methylthio)-benzofuran-5-ylacetic acid,
2-(3,4-dimethoxyphenyl)-benzofuran-5-ylacetic acid,
3-2-(4\u2032-hydroxy-3\u2032methoxyphenyl)-benzofuran-5-ylpropionic acid,
Methyl 2-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-benzofuran-5-ylacetate,
2-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-benzofuran-5-ylacetic acid,
3-2-(3,4-dimethoxyphenyl)-3-methylsufanyl-benzofuran-5-yl-propionic acid,
3-2-(3,4-dimethoxyphenyl)-3-methylsufanyl-benzofuran-5-yl-propionic acid methyl ester,
2-(3,4-dimethoxyphenyl)-3-methylsulfanyl-benzofuran-5-ylacetic acid,
2-(3,4-dimethoxyphenyl)-3-methylsulfanyl-benzofuran-5-ylacetic acid methyl ester,
3-2-(3,4-dimethoxy-phenyl)-benzofuran-5-yl-propionic acid,
3-2-(3,4-dimethoxy-phenyl)-benzofuran-5-yl-propionic acid methyl ester,
2-(3,4-dimethoxyphenyl)-benzofuran-5-ylacetic acid methyl ester,
Methyl 3-2-(4\u2032-acetoxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-yl-propionate,
Methyl 2-2-(4\u2032-acetyloxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-yl-acetate,
Methyl 3-2-{4\u2032-3-(diethylamino)propoxy-3\u2032-methoxy-phenyl}-3-(methylthio)-benzofuran-5-yl-1-propionate,
Methyl 2-4-(acetyloxy)-3-methoxyphenyl-1-benzofuran-5-yl-acetate,
Methyl 3-2-(4\u2032-acetoxy-3\u2032-methoxyphenyl)-benzofuran-5-ylpropionate,
Methyl 3-2-{4\u2032-3-(diethylamino)propoxy-3\u2032-methoxy-phenyl}-benzofuran-5-yl-1-propionate,
Methyl 2-(2-(4-acetoxy-3-methoxyphenyl)-3-(methylthio)benzofuran-5-yl)propanoate,
Methyl 2-(2-(4-acetoxy-3-methoxyphenyl)benzofuran-5-yl)propanoate;
N,N-diethyl 3-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-yl-propionamide,
N,N-dimethyl 3-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-yl-propionamide,
N-methyl 3-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-yl-propionamide,
N,N-diethyl 2-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-yl-acetamide,
N,N-dimethyl 2-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-yl-acetamide,
N-methyl 2-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-yl-acetamide,
(R)-2-(2-(2-(4-hydroxy-3-methoxyphenyl)-3-(methylthio)-benzofuran-5-yl-acetamide-4-methylpentanamide,
N-phenyl 3-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-yl-propionamide,
N-benzyl 3-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-yl-propionamide,
(R)-3-(2-2-(4-hydroxy-3-methoxyphenyl)-3-(methylsulfanyl)-1-benzofuran-5-yl-acetylamino-4-methylpentanamide,
N-phenyl 2-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-yl-acetamide,
N-benzyl 2-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-yl-acetamide,
2-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-ylacetamide,
3-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-ylpropionamide,
3-(2-(4-Hydroxy-3-methoxyphenyl)-3-(methylthio)benzofuran-5-yl)-N,N-dipropylpropanamide,
3-(2-(3,4-Dimethoxyphenyl)-3-(methylthio)benzofuran-5-yl)-N,N-dipropylpropanamide,
2-(2-(4-Hydroxy-3-methoxyphenyl)-3-(methylthio)benzofuran-5-yl)-N,N-dimethylacetamide,
N,N-Diethyl-2-(2-(4-hydroxy-3-methoxyphenyl)-3-(methylthio)benzofuran-5-yl)propanamide,
2-(2-(3,4-Dimethoxyphenyl)-3-(methylthio)benzofuran-5-yl)-N-propylacetamide,
N,N-Diethyl-3-(2-(3,4-dimethoxyphenyl)benzofuran-5-yl)propanamide,
N,N-Diethyl-2-(2-(4-hydroxy-3-methoxyphenyl)benzofuran-5-yl)acetamide,
2-(2-(4-Hydroxy-3-methoxyphenyl)benzofuran-5-yl)-N,N-dipropylacetamide,
N,N-Diethyl-2-(2-(4-hydroxy-3-methoxyphenyl)benzofuran-5-yl)propanamide,
2-(2-(4-Hydroxy-3-methoxyphenyl)benzofuran-5-yl)-N,N-dimethylpropanamide,
2-(2-(4-Hydroxy-3-methoxyphenyl)benzofuran-5-yl)-N,N-dipropylpropanamide,
2-(2-(4-Hydroxy-3-methoxyphenyl)benzofuran-5-yl)-N-propylpropanamide,
N,N-Diethyl-2-(2-(3,4-dimethoxyphenyl)benzofuran-5-yl)acetamide,
2-(2-(3,4-Dimethoxyphenyl)benzofuran-5-yl)-N,N-dimethylacetamide,
N-2-(3,4-Dimethoxy-phenyl)-benzofuran-5-yl-propionamide,
N-2-(3,4-Dimethoxy-phenyl)-benzofuran-5-yl-butyramide,
Butyl-2-(3,4-dimethoxy-phenyl)-benzofuran-5-yl-amine,
Methyl 3-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-benzofuran-5-yl-propionate,
2-2-(3-methoxy-4-methoxymethoxy-phenyl)-3-methylsulfanyl-benzofuran-5-yl-1-ethanol,
3-2-(3-methoxy-4-methoxymethoxy-phenyl)-3-methylsulfanyl-benzofuran-5-yl-propan-1-ol,
2-methoxy-4-5-(2-methoxy-ethyl)-benzofuran-2-yl-phenol,
Pentafluorophenyl 2-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-yl-acetate,
Pentafluorophenyl 3-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-yl-propionate,
Pentafluorophenyl 2-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-benzofuran-5-yl-acetate,
Pentafluorophenyl 3-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-benzofuran-5-yl-propionate,
2-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-yl-1-morpholino-1-ethanone,
2-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-yl-1-piperazino-1-ethanone,
2-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-yl-1-(4-benzylpiperazino)-1-ethanone,
2-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-yl-1-(4-benzylpiperidino)-1-ethanone,
3-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-yl-1-morpholino-1-propanone,
3-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-yl-1-piperazino-1-propanone,
3-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-yl-1-(4-benzylpiperazino)-1-propanone,
3-2-(4\u2032-hydroxy-3\u2032-methoxyphenyl)-3-(methylthio)-benzofuran-5-yl-1-(4-benzylpiperidino)-1-propanone,
Methyl 3-{2-4\u2032-(3-chloropropoxy)-3\u2032-methoxyphenyl-3-(methylthio)-benzofuran-5-ylpropionate,
2-(3,4-dimethoxyphenyl)-3-methylsulfanyl-benzofuran-5-ylacetic acid pentafluorophenyl ester,
3-2-(3,4-dimethoxy-phenyl)-3-methylsulfanyl-benzofuran-5-ylpropionic acid pentafluorophenyl ester,
2-(3,4-dimethoxy-phenyl)-benzofuran-5-ylacetic acid pentafluorophenyl ester,
3-2-(3,4-dimethoxy-phenyl)-benzofuran-5-ylpropionic acid pentafluorophenyl ester,
2-2-(3,4-dimethoxy-phenyl)-3-methylsulfanyl-benzofuran-5-yl-1-(4-phenyl-piperazin-1-yl)-ethanone,
3-2-(3,4-dimethoxy-phenyl)-3-methylsulfanyl-benzofuran-5-yl-1-(4-phenyl-piperazin-1-yl)-propan-1-one,
1-(4-benzyl-piperazin-1-yl)-2-2-(3,4-dimethoxy-phenyl)-3-methylsulfanyl-benzofuran-5-yl-ethanone,
1-(4-benzyl-piperazin-1-yl)-3-2-(3,4-dimethoxy-phenyl)-3-methylsulfanyl-benzofuran-5-yl-propan-1-one,
2-2-(3,4-dimethoxy-phenyl)-benzofuran-5-yl-1-(4-phenyl-piperazine-1yl)ethanone,
3-2-(3,4-dimethoxy-phenyl)-benzofuran-5-yl-1-(4-phenyl-piperazine-1yl)propan-1-one,
1-(4-benzyl-piperazin-1-yl)-2-2-(3,4-dimethoxy-phenyl)-benzofuran-5-yl-ethanone,
1-(4-benzyl-piperazin-1-yl)-3-2-(3,4-dimethoxy-phenyl)-benzofuran-5-yl-propan-1-one,
3-(2-(4-Hydroxy-3-methoxyphenyl)-3-(methylthio)benzofuran-5-yl)-1-(piperidin-1-yl)propan-1-one,
3-(2-(4-Hydroxy-3-methoxyphenyl)-3-(methylthio)benzofuran-5-yl)-1-(pyrrolidin-1-yl)propan-1-one,
3-(2-(3,4-Dimethoxyphenyl)-3-(methylthio)benzofuran-5-yl)-1-(piperidin-1-yl)propan-1-one,
3-(2-(3,4-Dimethoxyphenyl)-3-(methylthio)benzofuran-5-yl)-1-(pyrrolidin-1-yl)propan-1-one,
2-(2-(4-Hydroxy-3-methoxyphenyl)-3-(methylthio)benzofuran-5-yl)-1-(piperidin-1-yl)ethanone,
2-(2-(4-Hydroxy-3-methoxyphenyl)-3-(methylthio)benzofuran-5-yl)-1-((2S,6R)-2,6-dimethylmorpholino)ethanone,
2-(2-(4-Hydroxy-3-methoxyphenyl)-3-(methylthio)benzofuran-5-yl)-1-(4-methylpiperazin-1-yl)ethanone,
2-(2-(4-Hydroxy-3-methoxyphenyl)-3-(methylthio)benzofuran-5-yl)-1-(piperidin-1-yl)propan-1-one,
2-(2-(3,4-Dimethoxyphenyl)-3-(methylthio)benzofuran-5-yl)-1-(piperidin-1-yl)ethanone,
2-(2-(3,4-Dimethoxyphenyl)-3-(methylthio)benzofuran-5-yl)-1-(pyrrolidin-1-yl)ethanone,
2-(2-(3,4-Dimethoxyphenyl)-3-(methylthio)benzofuran-5-yl)-1-morpholinoethanone,
2-(2-(3,4-Dimethoxyphenyl)-3-(methylthio)benzofuran-5-yl)-1-(4-methylpiperidin-1-yl)ethanone,
2-(2-(3,4-Dimethoxyphenyl)-3-(methylthio)benzofuran-5-yl)-1-((2S,6R)-2,6-dimethylmorpholino)ethanone,
3-(2-(3,4-Dimethoxyphenyl)benzofuran-5-yl)-1-(pyrrolidin-1-yl)propan-1-one,
3-(2-(3,4-Dimethoxyphenyl)benzofuran-5-yl)-1-(piperidin-1-yl)propan-1-one,
3-(2-(3,4-Dimethoxyphenyl)benzofuran-5-yl)-1-morpholinopropan-1-one,
3-(2-(3,4-Dimethoxyphenyl)benzofuran-5-yl)-1-((2S,6R)-2,6-dimethylmorpholino)propan-1-one,
2-(2-(4-Hydroxy-3-methoxyphenyl)benzofuran-5-yl)-1-(piperidin-1-yl)ethanone,
2-(2-(4-Hydroxy-3-methoxyphenyl)benzofuran-5-yl)-1-(pyrrolidin-1-yl)ethanone,
2-(2-(4-Hydroxy-3-methoxyphenyl)benzofuran-5-yl)-1-((2S,6R)-2,6-dimethylmorpholino)ethanone,
1-(4-Benzylpiperidin-1-yl)-2-(2-(4-hydroxy-3-methoxyphenyl)benzofuran-5-yl)ethanone,
2-(2-(4-Hydroxy-3-methoxyphenyl)benzofuran-5-yl)-1-(4-phenylpiperazin-1-yl)ethanone,
2-(2-(4-Hydroxy-3-methoxyphenyl)benzofuran-5-yl)-1-(piperidin-1-yl)propan-1-one,
2-(2-(4-Hydroxy-3-methoxyphenyl)benzofuran-5-yl)-1-(4-methylpiperidin-1-yl)propan-1-one,
2-(2-(4-Hydroxy-3-methoxyphenyl)benzofuran-5-yl)-1-morpholinopropan-1-one,
2-(2-(4-Hydroxy-3-methoxyphenyl)benzofuran-5-yl)-1-((2S,6R)-2,6-dimethylmorpholino)propan-1-one,
2-(2-(4-Hydroxy-3-methoxyphenyl)benzofuran-5-yl)-1-(pyrrolidin-1-yl)propan-1-one,
2-(2-(3,4-Dimethoxyphenyl)benzofuran-5-yl)-1-(piperidin-1-yl)ethanone,
2-(2-(3,4-Dimethoxyphenyl)benzofuran-5-yl)-1-(4-methylpiperidin-1-yl)ethanone,
2-(2-(3,4-Dimethoxyphenyl)benzofuran-5-yl)-1-morpholinoethanone,
2-(2-(3,4-Dimethoxyphenyl)benzofuran-5-yl)-1-(pyrrolidin-1-yl)ethanone,
1-(4-Benzylpiperidin-1-yl)-2-(2-(3,4-dimethoxyphenyl)benzofuran-5-yl)ethanone,
2-(2-(3,4-Dimethoxyphenyl)benzofuran-5-yl)-1-(4-methylpiperazin-1-yl)ethanone,
3-(2-(4-Hydroxy-3-methoxyphenyl)benzofuran-5-yl)-1-(piperidin-1-yl)propan-1-one.
4. A pharmaceutical composition comprising an efficient amount of the compound represented by general formula (I) as set forth in claim 1 or the pharmaceutically acceptable salt thereof as an active ingredient in amount effective to treat or prevent cognitive function disorder, together with pharmaceutically acceptable carriers or diluents.
5. The pharmaceutical composition according to claim 4, wherein said cognitive function disorder is selected from Alzheimer type dementia, cerebrovascular type dementia, Pick’s disease, Creutzfeldt-jakob’s disease, dementia caused by cephalic damage or Parkinson’s disease.
6. A method of treating or preventing cognitive function disorder in a mammal comprising administering to said mammal an effective amount of novel derivatives represented by general formula (I) as set forth in claim 1 and the pharmacologically acceptable salt thereof, together with a pharmaceutically acceptable carrier thereof into the mammals including human suffering from said disease.
7. A use of the compound represented by general formula (I) as set forth in claim 1 or the pharmaceutically acceptable salt thereof for manufacture of medicines employed for treating or preventing cognitive function disorder in mammals including human as an active ingredient in amount effective to treat or prevent cognitive function disorder.
8. A health care food comprising benzofuran derivatives represented by general formula (I) as set forth in claim 1, or the pharmacologically acceptable salt thereof, together with a sitologically acceptable additive for the prevention and alleviation of cognitive function disorder.
9. The health care food according to claim 8, the health care food is a form of powder, granule, tablet, capsule or beverage.
10. A method of inhibiting accumulated beta-amyloid in a mammal comprising administering to said mammal an effective amount of novel derivatives represented by general formula (I) as set forth in claim 1 and the pharmacologically acceptable salt thereof, together with a pharmaceutically acceptable carrier thereof into the mammals including human suffering from said disease.